Company Short-Term Debt: Olema Pharmaceuticals (OLMA)

Olema Pharmaceuticals (OLMA) develops advanced inhibitors to block estrogen receptors, offering women hope for recovery. The business is currently funding costly final drug trials, where expenses are rising according to laboratory plans, and the indicator stands at 0.00. The stock price action shown below reflects the market valuation of the company, which is developing targeted therapy for female tumors and expanding its portfolio through various drug combinations.

This indicator aggregates all liabilities with a maturity of up to one year, reacting promptly to changes in liquidity. This metric assesses the business's ability to service current loans without compromising operational activities. For Olema Pharmaceuticals (OLMA), controlling such payments is critical due to costly oncology development and the risks of clinical failures. The dynamics of financial liabilities with a term of up to 12 months demonstrate the capital's resilience to market uncertainty.